Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Aung M. Tun"'
Autor:
Aung M. Tun, Yucai Wang, Seth Maliske, Ivana Micallef, David J. Inwards, Thomas M. Habermann, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Mohamed A Kharfan-Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Chimeric antigen receptor T-cell (CAR-T) therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and autologous stem
Externí odkaz:
https://doaj.org/article/46ad365a880749dfb154a7d75af7f42c
Autor:
Aung M. Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Thomas M. Habermann, Ivana Micallef, Patrick B. Johnston, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Han W. Tun, James R. Cerhan, Thomas E. Witzig, Grzegorz S. Nowakowski, Stephen M. Ansell
Publikováno v:
HemaSphere, Vol 7, Iss 4, p e869 (2023)
Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with co
Externí odkaz:
https://doaj.org/article/a4ab29ec31e74a8da4ff4f0b41f86131
Autor:
Alessia Castellino, Aung M. Tun, Yucai Wang, Thomas M. Habermann, Rebecca L. King, Kay M. Ristow, James R. Cerhan, David J. Inwards, Jonas Paludo, Stephen M. Ansell, Thomas E. Witzig, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-8 (2021)
Highlights Primary GI MCL is rare. These patients tend to be treated less aggressively in the frontline setting yet have similar outcomes as those with secondary GI MCL. Less aggressive frontline treatment for primary GI MCL is reasonable given decen
Externí odkaz:
https://doaj.org/article/81fd1dd792944ad59c170981903f0469
Autor:
Aung M. Tun, Seth Maliske, Yucai Wang, David J. Inwards, Thomas M. Habermann, Ivana Micallef, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Mohamed A Kharfan-Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston
Publikováno v:
Transplantation and Cellular Therapy. 28:610-617
Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who achieve progression-free survival (PFS) at 24 months (PFS24) after immunochemotherapy (IC) have excellent overall survival (OS) comparable to that of the age- and sex-matched gen
Autor:
Sanjal H Desai, Marcus P. Watkins, Reem Karmali, Gaurav Goyal, Mitchell Hughes, Arushi Khurana, Francisco Hernandez-Ilizaliturri, Nuttavut Sumransub, Joanna Zurko, Imran A. Nizamuddin, Haris Hatic, Daniel A Landsburg, Andrea Anampa-Guzman, Mehdi Hamadani, Yi Lin, Iris Isufi, Aung M Tun, Brian T. Hill, Deborah M. Stephens, Paolo F Caimi, Daniel A. Ermann, Brad S. Kahl, Grzegorz S. Nowakowski
Publikováno v:
Blood. 140:10391-10393
Autor:
Bei Hu, Shebli Atrash, Leah Cohen, Stefan K. Barta, Yumeng Zhang, Lubomir Sokol, Amy Ayers, Luis E Malpica Castillo, Steven R Hwang, N. Nora Bennani, David Wada, Aung M Tun, Tamara K. Moyo, Nilanjan Ghosh, Michi M Shinohara
Publikováno v:
Blood. 140:1488-1490
Autor:
William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed
Publikováno v:
Blood. 140:12781-12783
Autor:
William Wesson, Maggie Nelson, Muhammad Mushtaq, Rajat Bansal, Robert Kribs, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Al-Ola Abdallah, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Nausheen Ahmed
Publikováno v:
Blood. 140:12757-12759
Autor:
Allison C. Rosenthal, Stephen M. Ansell, Thomas E. Witzig, Ivana N. Micallef, Jose C. Villasboas, Mohamed A. Kharfan-Dabaja, Thomas M. Habermann, Umar Farooq, David J. Inwards, Jonas Paludo, Brian K. Link, Patrick B. Johnston, Grzegorz S. Nowakowski, Yucai Wang, Aung M. Tun, Seth M. Maliske, James R. Cerhan, Luis F. Porrata
Publikováno v:
Hematological Oncology. 39
e19501 Background: The current standard of care for patients with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL) following frontline immunochemotherapy (IC) is salvage therapy, followed by high-dose chemotherapy and autologous stem
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
Durvalumab is a therapeutic monoclonal antibody that blocks the checkpoint inhibitor, programmed death ligand 1 (PD-L1), resulting in T-cell activation and an antitumor response. Durvalumab is approved for patients with unresectable stage III non-sma